The cortisol-cortisone shuttle and hypertension.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Hypertension Research

Background:

• 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) is an enzyme complex crucial for cortisol metabolism.
• Deficiency in 11 beta-HSD can lead to mineralocorticoid hypertension, characterized by suppressed renin-angiotensin-aldosterone axis.
• Understanding this enzyme's role is vital for diagnosing and managing specific hypertensive conditions.

Purpose of the Study:

• To highlight the significance of 11 beta-HSD deficiency in pediatric mineralocorticoid hypertension.
• To outline diagnostic criteria for 11 beta-HSD deficiency.
• To discuss therapeutic strategies and implications for other forms of hypertension.

Main Methods:

• Assessment of cortisol production rate and plasma half-life.
• Analysis of urinary steroid metabolite profiles to determine cortisol/cortisone ratios.
• Clinical observation of patients presenting with hypertension and electrolyte imbalances.

Main Results:

• Congenital 11 beta-HSD deficiency presents with mineralocorticoid excess and suppressed renin-angiotensin-aldosterone axis.
• Diagnostic markers include reduced cortisol production, prolonged cortisol half-life, and elevated urinary cortisol to cortisone metabolite ratios.
• Treatment with dexamethasone effectively manages hypokalemia, though hypertension often requires additional antihypertensive medications.

Conclusions:

• Congenital 11 beta-HSD deficiency is a critical consideration in children with unexplained mineralocorticoid hypertension.
• Urinary steroid profiling is a key diagnostic tool.
• The enzyme's local activity in vasculature suggests potential roles in other hypertensive disorders.